Oncotelic Therapeutics, Inc.
OTLC
$0.09
$0.000.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -476.90% | 193.04% | 50.29% | 81.82% | -1,475.07% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 29.15% | 8.48% | 678.00% | -66.22% | -76.98% |
| Total Other Non-Cash Items | 192.24% | -8,796.77% | -101.69% | -87.82% | 3,380.54% |
| Change in Net Operating Assets | 68.03% | 6.46% | -20.35% | -3.19% | 628.40% |
| Cash from Operations | -143.26% | 24.43% | -60.73% | 27.44% | 45.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 365.19% | -15.63% | 290.24% | -81.36% | 51.72% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 365.19% | -15.63% | 290.24% | -81.36% | 51.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,547.73% | 225.71% | 88.87% | -181.90% | 165.75% |